Management of Neuroblastoma in Limited-resource Settings

Overview

Journal World J Clin Oncol

Publisher Baishideng Publishing Group

Specialty Oncology

Date 2020 Sep 4

PMID 32879849

Citations 7

Authors

Jaques Van Heerden

Mariana Kruger

Affiliations

Soon will be listed here.

Abstract

Background: Neuroblastoma (NB) is a heterogeneous disease with variable outcomes among countries. Little is known about NB in low- and middle-income countries (LMICs).

Aim: The aim of this review was to evaluate regional management protocols and challenges in treating NB in paediatric oncology units in LMICs compared to high-income countries (HICs).

Methods: PubMed, Global Health, Embase, SciELO, African Index Medicus and Google Scholar were searched for publications with keywords pertaining to NB, LMICs and outcomes. Only English language manuscripts and abstracts were included. A descriptive review was done, and tables illustrating the findings were constructed.

Results: Limited information beyond single-institution experiences regarding NB outcomes in LMICs was available. The disease characteristics varied among countries for the following variables: sex, age at presentation, MYCN amplification, stage and outcome. LMICs were found to be burdened with a higher percentage of stage 4 and high-risk NB compared to HICs. Implementation of evidence-based treatment protocols was still a barrier to care. Many socioeconomic variables also influenced the diagnosis, management and follow-up of patients with NB.

Conclusion: Patients presented at a later age with more advanced disease in LMICs. Management was limited by the lack of resources and genetic studies for improved NB classification. Further research is needed to develop modified diagnostic and treatment protocols for LMICs in the face of limited resources.

Citing Articles

Metabolomics-transcriptomics joint analysis: unveiling the dysregulated cell death network and developing a diagnostic model for high-grade neuroblastoma.

Zhang W, Zhang M, Sun M, Hu M, Yu M, Sun J Front Immunol. 2024; 14:1345734.

PMID: 38239355 PMC: 10794662. DOI: 10.3389/fimmu.2023.1345734.

Joint analysis of the metabolomics and transcriptomics uncovers the dysregulated network and develops the diagnostic model of high-risk neuroblastoma.

Du B, Zhang F, Zhou Q, Cheng W, Yu Z, Li L Sci Rep. 2023; 13(1):16991.

PMID: 37813883 PMC: 10562375. DOI: 10.1038/s41598-023-43988-w.

A Retrospective Analysis of the Therapeutic Outcomes of 117 Neuroblastoma Patients Treated at a Single Pediatric Oncology Center in China.

Yu U, Xu H, Chen S, Yi M, Liu C, Zhang X Cancer Control. 2023; 30:10732748231187837.

PMID: 37575028 PMC: 10426302. DOI: 10.1177/10732748231187837.

[Clinical efficacy of combined therapy in children with stage 4 neuroblastoma].

Liang W, Ye X, Zhong G, Chen J, Dai K, Cheuk K Zhongguo Dang Dai Er Ke Za Zhi. 2022; 24(7):759-764.

PMID: 35894190 PMC: 9336616. DOI: 10.7499/j.issn.1008-8830.2203049.

International Society of Paediatric Surgical Oncology (IPSO) Surgical Practice Guidelines.

Abib S, Chui C, Cox S, Abdelhafeez A, Fernandez-Pineda I, Elgendy A Ecancermedicalscience. 2022; 16:1356.

PMID: 35510137 PMC: 9023308. DOI: 10.3332/ecancer.2022.1356.

References

Panagopoulou P, Georgakis M, Baka M, Moschovi M, Papadakis V, Polychronopoulou S . Persisting inequalities in survival patterns of childhood neuroblastoma in Southern and Eastern Europe and the effect of socio-economic development compared with those of the US. Eur J Cancer. 2018; 96:44-53. DOI: 10.1016/j.ejca.2018.03.003. View

Whittle S, Smith V, Doherty E, Zhao S, McCarty S, Zage P . Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017; 17(4):369-386. DOI: 10.1080/14737140.2017.1285230. View

Rice H, Englum B, Gulack B, Adibe O, Tracy E, Kreissman S . Use of patient registries and administrative datasets for the study of pediatric cancer. Pediatr Blood Cancer. 2015; 62(9):1495-500. PMC: 4515152. DOI: 10.1002/pbc.25506. View

Smith M, Altekruse S, Adamson P, Reaman G, Seibel N . Declining childhood and adolescent cancer mortality. Cancer. 2014; 120(16):2497-506. PMC: 4136455. DOI: 10.1002/cncr.28748. View

Louis C, Shohet J . Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med. 2014; 66:49-63. PMC: 4418018. DOI: 10.1146/annurev-med-011514-023121. View

Hesseling P, Ankone K, Wessels G, Schneider J, du Plessis L, Moore S . Neuroblastoma in southern Africa: epidemiological features, prognostic factors and outcome. Ann Trop Paediatr. 2000; 19(4):357-63. DOI: 10.1080/02724939992202. View

Spix C, Pastore G, Sankila R, Stiller C, Steliarova-Foucher E . Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006; 42(13):2081-91. DOI: 10.1016/j.ejca.2006.05.008. View

Kyu H, Pinho C, Wagner J, Brown J, Bertozzi-Villa A, Charlson F . Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013: Findings From the Global Burden of Disease 2013 Study. JAMA Pediatr. 2016; 170(3):267-87. PMC: 5076765. DOI: 10.1001/jamapediatrics.2015.4276. View

Coovadia H, Jewkes R, Barron P, Sanders D, McIntyre D . The health and health system of South Africa: historical roots of current public health challenges. Lancet. 2009; 374(9692):817-34. DOI: 10.1016/S0140-6736(09)60951-X. View

10.

Lucena J, Seixas Alves M, Abib S, Souza G, Neves R, Caran E . CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS AND SURVIVAL OUTCOMES OF CHILDREN WITH NEUROBLASTOMA: 21 YEARS OF EXPERIENCE AT THE INSTITUTO DE ONCOLOGIA PEDIÁTRICA, IN SÃO PAULO, BRAZIL. Rev Paul Pediatr. 2018; 36(3):254-260. PMC: 6202906. DOI: 10.1590/1984-0462/;2018;36;3;00007. View

11.

Ward E, DeSantis C, Robbins A, Kohler B, Jemal A . Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014; 64(2):83-103. DOI: 10.3322/caac.21219. View

12.

Parikh N, Howard S, Chantada G, Israels T, Khattab M, Alcasabas P . SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings. Pediatr Blood Cancer. 2015; 62(8):1305-16. PMC: 5132052. DOI: 10.1002/pbc.25501. View

13.

Viana M, Fernandes R, de Oliveira B, Murao M, de Andrade Paes C, Duarte A . Nutritional and socio-economic status in the prognosis of childhood acute lymphoblastic leukemia. Haematologica. 2001; 86(2):113-20. View

14.

Ibrahim M, Abdullahi S, Hassan-Hanga F, Atanda A . Pattern of childhood malignant tumors at a teaching hospital in Kano, Northern Nigeria: A prospective study. Indian J Cancer. 2014; 51(3):259-261. DOI: 10.4103/0019-509X.146765. View

15.

Stefan D, Stones D, Wainwright R, Kruger M, Davidson A, Poole J . Childhood cancer incidence in South Africa, 1987-2007. S Afr Med J. 2015; 105(11):939-47. DOI: 10.7196/SAMJ.2015.v105i11.9780. View

16.

Bahoush Mehdiabadi G, Arab E, Arjmandi Rafsanjani K, Ansari S, Moinzadeh A . Neuroblastoma in Iran: an experience of 32 years at a referral childrens hospital. Asian Pac J Cancer Prev. 2013; 14(5):2739-42. DOI: 10.7314/apjcp.2013.14.5.2739. View

17.

Kitonyi G, Macharia W, Mwanda O, Pamnani R . Clinico-pathologic characteristics and treatment outcomes in children with neuroblastoma at the Kenyatta National Hospital, Nairobi. East Afr Med J. 2011; 86(12 Suppl):S39-46. DOI: 10.4314/eamj.v86i12.62899. View

18.

Heck J, Ritz B, Hung R, Hashibe M, Boffetta P . The epidemiology of neuroblastoma: a review. Paediatr Perinat Epidemiol. 2009; 23(2):125-43. DOI: 10.1111/j.1365-3016.2008.00983.x. View

19.

Stefan C, Bray F, Ferlay J, Liu B, Parkin D . Cancer of childhood in sub-Saharan Africa. Ecancermedicalscience. 2017; 11:755. PMC: 5574662. DOI: 10.3332/ecancer.2017.755. View

20.

Shuangshoti S, Shuangshoti S, Nuchprayoon I, Kanjanapongkul S, Marrano P, Irwin M . Natural course of low risk neuroblastoma. Pediatr Blood Cancer. 2011; 58(5):690-4. DOI: 10.1002/pbc.23325. View